Related Experiment Videos
Phosphonate-containing inhibitors of tyrosine-specific protein kinases
1Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Abstract:
Tyrosine-specific protein kinases (TPK) are important signal transducing enzymes involved in normal cellular growth and differentiation and have been implicated in the etiology of a number of human neoplastic processes. Efforts to develop agents which inhibit the function of these enzymes by interfering with the binding of substrate have been limited by the lack of detailed three-dimensional structural data. Many inhibitors of substrate binding share a common styrene nucleus 1 which has been postulated to function as a conformationally constrained analogue of tyrosine. In an effort to develop high-affinity compounds based on this hypothesis, a number of derivatives were synthesized in which either methylphosphonate (4a-c) or (hydroxymethyl)phosphonate (3a-c) were appended to the aromatic 4-position of styrene-containing moieties. The intent of this approach was to prepare hydrolytically stable analogues which expressed additional enzyme recognition features present during the phosphorylation of tyrosine itself. None of the analogues showed inhibitory activity up to the maximum concentration tested (1000 microM) when assayed against autophosphorylation of A-431-derived epidermal growth factor receptor (EGFR) or p56lck (autophosphorylation and transphosphorylation of rabbit muscle enolase). Additionally, a series of naphthalene-based inhibitors including (1-naphthalenylhydroxymethyl)phosphonic acid (14), its known 2-positional isomer 16, and sulfonate (19, 20) and phosphate derivatives (17, 18) were also tested under similar conditions. Only (2-naphthalenyl-hydroxymethyl)phosphonic acid (16) showed activity (IC50 = 250 microM in EGFR, in agreement with the reported literature value). These results suggest that the interaction of styrene-based inhibitors with the substrate binding domain of TPKS may not occur in a manner analogous to the interaction of tyrosine with this domain.
Insights
Tyrosine-specific protein kinase (TPK) inhibitors were synthesized to target cancer pathways. Most compounds showed no activity, suggesting styrene-based inhibitors may not mimic tyrosine binding effectively.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Enzymology
Background:
- Tyrosine-specific protein kinases (TPKs) are crucial signaling enzymes implicated in cancer development.
- Developing TPK inhibitors is vital for cancer therapy, but structural data for substrate-binding inhibitors is limited.
- Styrene-based compounds are hypothesized to act as constrained tyrosine analogues for inhibitor design.
Purpose of the Study:
- To synthesize and evaluate novel styrene and naphthalene derivatives as potential TPK inhibitors.
- To investigate if phosphonate and sulfonate/phosphate analogues can serve as stable, high-affinity inhibitors.
- To explore the binding interactions of these inhibitors with TPKs.
Main Methods:
- Synthesis of methylphosphonate and (hydroxymethyl)phosphonate styrene derivatives.
- Synthesis of naphthalene-based phosphonic acid, sulfonate, and phosphate derivatives.
- Enzyme inhibition assays using epidermal growth factor receptor (EGFR) and p56lck.
Main Results:
- None of the synthesized styrene derivatives exhibited inhibitory activity against EGFR or p56lck up to 1000 microM.
- (2-Naphthalenyl-hydroxymethyl)phosphonic acid demonstrated inhibitory activity against EGFR with an IC50 of 250 microM.
- Other naphthalene derivatives, including sulfonate and phosphate analogues, showed no significant inhibitory activity.
Conclusions:
- The hypothesis that styrene-based inhibitors mimic tyrosine binding to TPKs may be incorrect.
- The naphthalene-based compound (2-naphthalenyl-hydroxymethyl)phosphonic acid shows moderate inhibitory activity, warranting further investigation.
- Further research is needed to understand the precise binding mechanisms of TPK inhibitors.